Strategia Therapeutics presents E6201, a targeted TKI for acute myeloid leukemia, at the 2015 Texas Life Science Forum

Strategic Therapeutics, inc. (ST) was founded as Boston Strategics Corporation in Massachusetts in April 2012, and in November, 2013, opened an office in Houston in the vicinity of the Texas Medical Center. The company name was changed in 2015 more accurately describe the company’s vision to change the existing drug research and development paradigm by creating a nimble approach to drug development, the reducing overall costs and time to market, and making new drug products available to patients whose medical needs would otherwise be unmet.

ST is an integrated R&D company that utilizes the expertise of its highly experienced core staff to support pharmaceutical and biotech drug development. ST can significantly optimize drug development with its streamlined structure and team of in-house drug development experts who have over 140 years’ experience in biologic and small molecule cancer drug development from discovery to global approval and life-cycle management.

The initial focus of ST has been to develop partnerships with medium size Japanese pharmaceutical companies, assisting with their strategic and tactical drug development needs in the U.S. ST has strong links to Texas, including a Strategic Alliance Agreement with MD Anderson Cancer Center and we are actively conducting several preclinical and clinical studies for our client partners.

Additionally, we develop our own proprietary compounds by in-licensing clinical stage compounds from pharma companies. The first compound is a dual-targeted anti-cancer molecule for hematologic and solid tumor malignancies under an agreement with Eisai Pharmaceuticals. Our first drug product is E6201, a small molecule dual mitogen-activated protein kinase/ FMS-like tyrosine kinase 3 (MEK1/FLT3) inhibitor. Our first indication for development is E6201 for the treatment of patients with relapsed or refractory acute myelogenous leukemia (AML). A second targeted compound is poised for in-licensure. Both compounds serve unmet needs for patients with gene mutations and failure of standard therapies for treatment of solid tumors and hematologic malignancies. We are poised to raise money as needed to assist in these development efforts.

ST currently has a Boston- and Texas-based Management Team with breadth and depth of skills, experience and track record for successful development of products from preclinical, manufacturing, clinical development, FDA submissions, maintenance, product approvals and life-cycle management.
Contact:
Strategia Therapeutics, Inc.
+1-781-761-0123 (office)
Contact@StrategiaTx.com (email)
StrategiaTx.com (website)

TapBoost^® Technology: Enhanced Production for Difficult-to-Produce Proteins

PEGS Boston the essential protein engineering summit

Abstract
Therapeutic recombinant proteins produced using mammalian expression systems often have misfolding issues and are stuck in the endoplasmic reticulum by cellular quality control system, resulting in poor expression and yields. We have developed a novel technology called TapBoost^® technology, which assists proper protein folding and cellular quality control systems specifically for a targeted protein. A proprietary protein (TapBoost^®) is expressed together with a therapeutic protein (targeted protein), followed by the interaction between TapBoost^® and the targeted protein, resulting in enhanced production of the targeted protein. TapBoost^® has successfully enhanced the production of many therapeutic recombinant proteins including monoclonal antibodies and Fc fusion proteins. Importantly, monoclonal antibodies produced by the technology retained the ability to bind to the corresponding epitope, and enzymes retained their biological activity. Intriguingly, the expression of difficult-to-express proteins such as G protein-coupled receptor (GPCR) are improved by the technology and GPCR proteins expressed using TapBoost^® are strongly activated after the ligand binding, and moreover the aggregation of produced proteins is significantly diminished when the aggregation-prone protein is expressed by TapBoost^® technology. This unique mechanism of action enables TapBoost^® to combine with other existing expression technologies to enhance the production of therapeutic proteins.

Presentation  “TapBoost^® Breakthrough Platform to Improve Protein Production-”

Click to view PDF version

Dr. Akinori Hishiya, Director of Biology
Paul Wengender, Chief Strategist, TapBoost^® Technology

TapBoost^® Technology: Broad Spectrum of Use for Novel Chaperone-driven Platform.

Abstract

Dr. Akinori Hishiya discovered the specific amino acid sequence that enhances protein production and named “BSC1” sequence, the core component of the TAPBOOST^® technology platform. This exciting chaperone-driven productivity enhancement exploits the BSC1 sequence to 1) enhance biotherapeutic protein and antibody yields, 2) rescue difficult-to-express protein projects, and 3) efficiently produce research quantities of important disease-relevant proteins.

Dr. Akinori Hishiya, Director of Biology
Paul Wengender, Chief Strategist, TapBoost^® Technology

 

Click for full PDF